Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.
Read Full NewsThe FDA has approved asundexian, the first factor XIa inhibitor indicated to reduce recurrent stroke after a noncardioembolic ischemic stroke or high-risk TIA, based on phase 3 OCEANIC-STROKE data.
An analysis of the PROSPECT trial reported that consistent use of transcutaneous afferent patterned stimulation was associated with improvement in underlying tremor severity in patients with essential tremor.
A study of deceased former NFL players estimated that nearly 75% had CTE neuropathology, while a phase 3 trial is evaluating whether F-18 FNT-PET imaging could help identify disease-associated patterns in living patients.
Odinachi Oguh, MD, movement disorder specialist at the Cleveland Clinic Lou Ruvo Center for Brain Health, shares clinical perspectives on biomarkers, aging, non-motor symptoms, and prodromal disease from the 2026 MDS Congress.
At a NeurologyLive Clinical Forum in New York, Mary Ann Piccone, MD, of Holy Name Medical Center, led a wide-ranging discussion among MS specialists on the limits of current high-efficacy therapies, the pipeline of emerging agents, and the gap between physician and patient treatment priorities.
Rezpegaldesleukin's Early Treg Signal in AD: Emma Guttman-Yassky, MD
Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control
1.
The origin of BPH and prostate cancer in different prostate zones and the impact on the incidence of prostate cancer
2.
A new therapeutic approach could help tackle radiation resistance in childhood brain tumors
3.
Diet and Prostate Cancer; TTFields OK'd for NSCLC; Cancer Studies Retracted
4.
Transperineal Biopsy IDs Active Surveillance Candidates
5.
combating racial discrimination in next-generation breast cancer screening.
1.
The Oncologist’s Edge: Tools, Trials, and Tech Transforming Treatment
2.
AI-Powered Strategies for Precision and Improved Outcomes in Esophageal Cancer, a Global Health Crisis
3.
Obesity is a major risk factor for cancer
4.
Future-Ready Cancer Screening: What Every Clinician Should Know in 2025
5.
Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
2.
Understanding Anemia: Causes, Symptoms and Treatment
3.
Navigating the Complexities of Ph Negative ALL - Part I
4.
Early Warning Signs of Cancer
5.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge